---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000458"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:24:45.111975+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Heron reports preliminary FY2022 revenue $106.7M (+24% YoY); oncology franchise beats guidance

## Summary
- Preliminary full-year 2022 net product sales $106.7M, up 24% YoY; oncology franchise $96.6M vs guidance $93-95M.
- Q4 2022 ZYNRELEF net sales ~$3.8M, up 40% vs Q3; demand units 20,765 (+38%).
- Full-year 2023 oncology franchise guidance $99-103M; APONVIE launch expected Q1 2023.
- sNDA for expanded ZYNRELEF indication submitted to FDA Dec 2022; 10-month action date.
- NOPAIN Act provides separate CMS reimbursement for ZYNRELEF through Dec 2027.

## SEC filing metadata
- accession: 0000950170-23-000458
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/0000950170-23-000458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/hrtx-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000458
- JSON: https://secwatch.observer/filing/0000950170-23-000458.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000458.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ reported Three and twelve months ended December 31, 2022 results: revenue The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont.
  - Period: Three and twelve months ended December 31, 2022
  - Revenue: The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont
  - Result: preliminary results
  source text: On January 9, 2023, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain of its preliminary financial results for the three and twelve months ended December 31, 2022 (the “Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/0000950170-23-000458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.